#Canada #Calgary #Innocan Pharma #Chronic Pain #LPT Technology

Innocan Pharma Reports 2025 Financial Results

Innocan Pharma Corporation, a leading pharmaceutical technology enterprise, has announced its audited financial results for the fiscal year ending December 31, 2025. The company, operating under the ticker symbols CSE: INNO, FSE: IP4, and OTC: INNPF, reported revenues of $26.6 million, representing a 9.6% decrease from the previous year. CEO Iris Bincovich remarked on the company’s steadfast commitment to advancing innovative healthcare solutions, particularly in the field of chronic pain management.

Innocan Pharma is recognized for its development of non-opioid treatments, utilizing its proprietary drug delivery platform for both human and veterinary applications. Alongside its pharmaceutical segment, the company also has a wellness division that markets various beauty products aimed at promoting healthier lifestyles. Bincovich expressed optimism about the company's trajectory, anticipating significant growth opportunities, especially in light of a forthcoming U.S. public offering aimed at maximizing shareholder value.

Fiscal Overview

The reported financials for 2025 indicate a gross profit of $23.9 million, down 8.6% compared to 2024, with a gross margin of an impressive 89.9%. This margin remained robust despite overall revenue declines. Operating loss reported was $1.255 million, a slight increase of 0.7% from the prior year, indicating stable performance amidst challenging market conditions.

Sales trends portray a more favorable outlook with moderating declines throughout the quarters. Roni Kamhi, CEO of B.I. Sky Global and COO at Innocan Pharma, indicated that strategic maneuvers to mitigate tariff implications and optimize the supply chain have yielded significant cost savings. These steps have fortified the company’s market position, ensuring robust results as conditions gradually improve.

Continued Commitment to Innovation

Innocan Pharma's dual-pronged focus on pharmaceuticals and consumer wellness remains a cornerstone of its strategy. The pharmaceutical segment is especially notable for its commitment to developing cutting-edge cannabinoid-based delivery systems for treating various ailments. The flagship technology is the LPT-CBD loaded liposome platform, which allows for precise dosing and controlled release of CBD into the bloodstream. Research for this platform is actively undergoing preclinical trials, targeting both pain relief and epilepsy.

On the consumer side, Innocan has a vested interest in the self-care market, with an extensive portfolio of products designed for enhanced quality of life. The company's strategic partnership with B.I. Sky Global Ltd., in which it holds a 60% share, aims to leverage advanced online sales methodologies, further pushing the boundaries of consumer engagement and accessibility.

Looking Ahead

As 2026 progresses, Innocan Pharma is poised to achieve significant milestones in its product offerings, regulatory approvals, and market entry strategies. Commitment to addressing chronic pain—both in humans and animals—remains central to Innocan’s mission, with the vet sector witnessing notable recognition from regulatory bodies like CVM for its innovative LPT technology validated through rigorous studies.

In summary, Innocan Pharma remains resilient, showcasing a focus on sustainable growth, high-quality products, and the overarching goal of enhancing patients’ lives through innovation and strategic market moves. As the company prepares for its public offering, it continues to strengthen its commitment to delivering value for its investors amid the evolving healthcare landscape.

For full disclosures and insights, visit Innocan Pharma's official website: www.innocanpharma.com